Prof. Dr. med. Georg Marckmann, MPH

Institut für Ethik, Geschichte und Theorie der Medizin

Ludwig-Maximilians-Universität München
Lessingstr. 2
80336 München
Phone: +49 89 2180 72775
Email: marckmann@lmu.de

University training and degree

2004 Liscense as Physician (‘Approbation’)
1999 – 2000 Master of Public Health, Harvard School of Public Health, Boston, USA
1989 – 1995 M.A. in Philosophy, University of Tübingen
1987 – 1997 Medical School, University of Tübingen

Advanced academic qualifications

2003 Habilitation for “Ethics in Medicine”, University of Tübingen. Mentor: Prof. Dr. Dr. Urban Wiesing
1997 Doctoral degree in Medicine (Dr. med.), summa cum laude. Supervisors: Prof. Dr. J. Dichgans and Prof. Dr. Eckhard Altenmüller

Postgraduate professional career

Since 2010 Full Professor of Ethics, History, and Theory of Medicine, director of the Institute of Ethics, History, and Theory of Medicine, LMU Munich
1998 – 2010 Assistant Professor and Vice Director (since 2004) at the Institute of Ethics and History of Medicine, University of Tübingen

Professional memberships (selection)

Since 2017 Board Member, German-speaking Union for Advance Care Planning
Since 2015 Vice President, (German) Society for Law and Politics in Health Care
Since 2012 President, German Medical Ethics Society

Scholarships and awards

2004 Young Researcher Award of University of Tübingen for habilitation thesis
1992 – 1995 DFG-scholarship in Postgraduate College “Ethics in the Sciences and Humanities”, University of Tübingen

Service on scientific advisory boards

Central Ethics Commission of the German Federal Physician Association
Institutional Review Board of the Medical Faculty of LMU Munich
Clinical Ethics Committee of the University Hospital Munich


a) Articles published by outlets with scientific quality assurance, book publications and works accepted for publication, but not yet published


1. Klingler, C., Ismail, F., Marckmann, G., and Kuehlmeyer, K. (2018). Medical professionalism of foreign-born and foreign-trained physicians under close scrutiny: A qualitative study with stakeholders in Germany. PLoS One 13, e0193010.

2. Schleidgen, S., Thiersch, S., Würstlein, R., and Marckmann, G. (2017). How do patients experience individualized medicine? A qualitative interview-based study of gene expression analyses in the treatment of breast cancer Geburtsh Frauenheilk 77, 984-992.

3. Friedrich, O., Hemmerling, K., Kuehlmeyer, K., Nortemann, S., Fischer, M., and Marckmann, G. (2017). Principle-based structured case discussions: do they foster moral competence in medical students? – A pilot study. BMC Med Ethics 18, 21.

4. Klingler, C., and Marckmann, G. (2016). Difficulties experienced by migrant physicians working in German hospitals: a qualitative interview study. Hum Resour Health 14, 57.

5. Klingler, C., in der Schmitten, J., and Marckmann, G. (2016). Does facilitated Advance Care Planning reduce the costs of care near the end of life? Systematic review and ethical considerations. Palliat Med 30, 423-433.

6. Marckmann, G., Schmidt, H., Sofaer, N., and Strech, D. (2015). Putting public health ethics into practice: A systematic framework. Frontiers in Public Health 3. DOI: 10.3389/fpubh.2015.00023.Available online at www.frontiersin.org/Journal/10.3389/fpubh.2015.00023

7. In der Schmitten, J., Lex, K., Mellert, C., Rotharmel, S., Wegscheider, K., and Marckmann, G. (2014). Implementing an advance care planning program in German nursing homes: results of an inter-regionally controlled intervention trial. Dtsch Arztebl Int 111, 50-57.

8. Rogowski, W.H., Grosse, S.D., Schmidtke, J., and Marckmann, G. (2014). Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most? European journal of human genetics : EJHG 22, 25-31.

9. Schleidgen, S., Klingler, C., Bertram, T., Rogowski, W.H., and Marckmann, G. (2013). What is personalized medicine: sharpening a vague term based on a systematic literature review. BMC Med Ethics 14, 55.

10. Winkler, E.C., Hiddemann, W., and Marckmann, G. (2011). Ethical assessment of life-prolonging treatment. Lancet Oncol 12, 720-722.